Suzetrigine · Journavx
Small molecule
Also known as VX-548
Evidence outlook
Approved: Acute Pain
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Diabetic Peripheral Neuropathic Pain · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05558410 NCT05558410 · Acute Pain Patients were randomly assigned to suzetrigine, hydrocodone/acetaminophen or placebo, with patients, care providers, investigators and assessors all blinded. A power calculation set a target of about 1,000 patients, and 1,118 were enrolled. Suzetrigine beat placebo on the primary pain endpoint over 48 hours (least-squares mean 118.4 vs 70.1, p<0.0001). Registry: NCT05558410 | 3 | Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug) 2023-08-25 | Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug): Placebo 70.1 units on a scale (Standard Error 6.1) | Suzetrigine (SUZ) 118.4 units on a scale (Standard Error 4.3) | Reliable signal | link ↗ |
View 1 more trial
NCT05553366 NCT05553366 · Acute Pain Patients were randomly assigned to suzetrigine, hydrocodone/acetaminophen or placebo in a double-blind design. A power calculation set a target of about 1,000 patients, and 1,075 were enrolled. Suzetrigine beat placebo on the primary pain endpoint over 48 hours (least-squares mean 99.9 vs 70.6, p=0.0002). Registry: NCT05553366 | 3 | Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug) 2023-12-15 | Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug): Placebo 70.6 units on a scale (Standard Error 6.3) | Suzetrigine (SUZ) 99.9 units on a scale (Standard Error 4.5) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (25)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (2)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2 (1)
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other Voltage-gated sodium channel NaV1.8 drugs
JMKX000623, VX-993. Compare all 3 Voltage-gated sodium channel NaV1.8 drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Acute Pain: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Suzetrigine (Journavx): this drug | Approved | Small molecule | Voltage-gated sodium channel NaV1.8 | Reliable signal | NCT05553366: Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug): Placebo 70.6 units on a scale (Standard Error 6.3) | Suzetrigine (SUZ) 99.9 units on a scale (Standard Error 4.5) NCT05558410: Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug): Placebo 70.1 units on a scale (Standard Error 6.1) | Suzetrigine (SUZ) 118.4 units on a scale (Standard Error 4.3) | |
| Bupivacaine Liposome (Exparel) | Approved | Small molecule | Amide Local Anesthetic | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-2129 | Phase 1(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(30 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Journavx (Suzetrigine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
December 2026 (2)
2027 (19)
January 2027 (2)
February 2027 (1)
What to watch
March 2027 (2)
What to watch
What to watch
April 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (3)
What to watch
What to watch
What to watch
July 2027 (2)
August 2027 (2)
October 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (3)
What to watch
What to watch
What to watch
2028 (6)
January 2028 (1)
What to watch
February 2028 (1)
What to watch
July 2028 (1)
What to watch
August 2028 (1)
What to watch
September 2028 (1)
What to watch
October 2028 (1)
What to watch
2029 (2)
January 2029 (1)
What to watch
April 2029 (1)
What to watch
2030 (1)
December 2030 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent